Dr. Zibelman on Determining Treatments for Patients with RCC

Matthew R. Zibelman, MD
Published: Tuesday, Oct 03, 2017



Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

After standard therapy with tyrosine kinase inhibitors (TKIs), there is currently no good data to guide what regimen should come next, states Zibelman. Nivolumab (Opdivo) has been well tolerated, which has made it appealing to many patients. Additionally, patients with bone metastases tend to respond well to cabozantinib (Cabometyx).
 


Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

After standard therapy with tyrosine kinase inhibitors (TKIs), there is currently no good data to guide what regimen should come next, states Zibelman. Nivolumab (Opdivo) has been well tolerated, which has made it appealing to many patients. Additionally, patients with bone metastases tend to respond well to cabozantinib (Cabometyx).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x